Anti Gliadin peptide
Mouse monoclonal antibody
Cat.No. HYB 314-01
Preparation: Protein-A/G purified
Content: Available in 200 µL and 1 mL
Concentration: 1 mg/mL
Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
Storage: In the dark at 4-8ºC
Celiac disease is associated with a CD4+ T-cell response to epitopes of gliadin presented by HLA-DQ2 or -DQ8 class II MHC molecules. These epitopes are present in a 33-mer peptide of wheat alpha-gliadin, residues 56-88, which is resistant to digestion and forms a substrate for tissue transglutaminase (TG2), generating the glutamic acid residues essential for binding to HLA-DQ2. The immunogen corresponds to a deamidated form of a region that includes the T-cell epitopes, including the immunodominant PQPQLPY region and two PXPQP motifs associated with binding to IgA from patients with celiac disease. Complete homology exists between residues 63-73, 70-80 and 77-87 of wheat alpha gliadin.
Gliadin-related peptide Lys57-Glu65-[alpha-gliadin (58-73)] (KLQPFPQPELPYPQPQ) coupled to immunogenic carrier protein.
HYB 314-01 is specific for the deamidated peptide but cross-reacts about 5% with the non-deamidated peptide KLQPFPQPQLPYPQPQ.
The epitope is located in the Lys57-Glu65-[alpha-gliadin (58-73)] (KLQPFPQPELPYPQPQ) peptide.
HYB 314-01 reacts with both the deamidated peptide (KLQPFPQPELPYPQPQ) and non-deamidated petide (KLQPFPQPELPYPQPQ) when these are coated directly in an immunoplate, but approx. 20-fold higher concentrations of antibody are needed to produce the same signal with the non-deamidated peptide.
| Method | Usability | Dilution guideline | References |
| ELISA | Yes | 1: 64,000 | 1 |
| Immunoblotting | ND | ||
| Immunohistochemistry | ND |
1. Skovbjerg H, Koch C, Anthonsen D, Sjostrom H (2004) Deamidation and cross-linking of gliadin peptides by transglutaminases and the relation to celiac disease. Biochim Biophys Acta 1690:220-230.
2. Mowat AM (2003) Coeliac disease - a meeting point for genetics, immunology, and protein chemistry. Lancet 361:1290-2.
